Teleflex introduces Arrow® NextStep® Antegrade Dialysis Catheter Teleflex Incorporated, a leading global provider of medical devices for critical care and surgery, has expanded its interventional access portfolio with the Arrow NextStep Antegrade catheter, now available for sale in the United States. The Arrow NextStep Antegrade is a chronic hemodialysis catheter that combines a step-tip catheter’s ease of insertion with a split-tip catheter’s sustained high flow. Its unique tip is designed for smooth, over-the-wire transitions during catheter insertions and exchanges. To reduce recirculation and deliver high flow, the Arrow Next-
Step Antegrade’s tip provides two unique, complementary features: 1. The openings are reversed to take better advantage of blood flow dynamics within the heart. 2. The distal tips of both lumens are significantly separated to help enhance flow and minimize recirculation. The NextStep Antegrade is one of several options in the Arrow dialysis catheter portfolio, a portfolio built with clinical needs and preferences—and the patient’s needs—in mind. The Arrow chronic hemodialysis catheter portfolio offers both split-tip and step-tip catheters for
both retrograde and antegrade insertion techniques. The Arrow NextStep product family consists of step-tip catheters that can be tunneled using the retrograde or antegrade technique. The Arrow Cannon® II Plus and the Arrow Edge® products are split-tip catheters that can be tunneled retrograde or antegrade, respectively. Teleflex offers catheter sets with Arrow Simplicity® colorcoded micro puncture introducers and Arrow SmartSeal® Hemo-
static Peelable Dialysis Sheaths. Teleflex also provides an offering of ARROWg+ard Blue® Acute Hemodialysis Catheters in the ErgoPack™ System. These acute catheters are treated with ARROWg+ard®, Teleflex’s proprietary chlorhexidine-based antimicrobial technology. “Our interventional access products highlight our commitment to partnering with customers to help enhance patient outcomes. Our goal is to offer products that are designed for optimal performance,” said Linda Beneze, VP & GM, Specialty Products Division, Teleflex Incorporated.
PeriGen, Inc. names Allscripts Mentor Capital acquires 50% Executive Matthew Sappern of Brighter Day Health for $5M Mentor Capital, Inc. recently plus for all parties involved with Chief Executive Officer
PeriGen, Inc., the leader in perinatal-specific clinical decision support for hospitals, recently announced that it has appointed Matthew Sappern as the Chief Executive Officer, effective immediately. “We are delighted that Matt Sappern is coming on board to lead PeriGen. Matt’s proven expertise in driving the growth of sophisticated, groundbreaking healthcare IT products is a great fit for PeriGen.” Sappern, 45, joins PeriGen from his position as Senior Vice President, Client Sales at Allscripts,
a $1.3 billion global leader in the electronic medical records industry. At Allscripts, Sappern’s Client Sales team achieved record bookings in 2011. Sappern joined Allscripts in 2010 following its merger with Eclipsys, where he served as a corporate officer and Senior Vice President of Professional Services responsible for directing the Services division, encompassing the company’s consulting, implementation, and education and training services. Before that, he served as Senior Vice President of Technology Solution Services at Eclipsys, which he joined in 2003, after serving in leadership roles at WebMD, Time Warner, Primedia and Young & Rubicam. David Jahns, member of PeriGen’s Board of Directors, and Managing Director of Galen Partners, said, “We are confident that as chief executive officer, Matt Sappern will significantly expand PeriGen’s market footprint so that the breadth and depth of its innovative, clinical decision support technologies can touch more patients.”
16 | February 2012 Healthcare Executive
announced that it has executed a long-term funding agreement to receive a current 50% ownership in Brighter Day Health, LLC, pending their expected shareholder approval. Brighter Day provides face-to-face doctor interaction through secure computer video set-ups for ultra-economic health care delivery at nursing homes and similar treatment facilities. Mentor Capital is to provide $5.0 million in future growth funding for Brighter Day Health to continue its multi-state expansion plan. “Telemedicine is the fastest growing method of delivering face-to-face healthcare to patients in the United States. Brighter Day Health has been an early leader in this field and is partnering with Mentor Capital to finance our accelerated facility and video system additions.” “Reducing the cost and inconvenience of the routine or follow-up doctor visit for often challenged cancer or other patients is an obvious
a compromised patient,” says Mentor Capital CEO, Chester Billingsley. Edward Mashek, the CEO of Brighter Day Health, explains, “Telemedicine is the fastest growing method of delivering face-to-face healthcare to patients in the United States. Brighter Day Health has been an early leader in this field and is partnering with Mentor Capital to finance our accelerated facility and video system additions.” The Brighter Day Health portfolio addition brings Mentor Capital cancer and financial assets to $10 million from $1.0 million in November 2011. Mentor has approximately 2.9 million basic shares outstanding and has traded in the quarterly range of $0.10 to $0.26 per share.